Pterostilbene Amino Acid Carbonates for Soluble Stable NASH Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are inadequate, with no FDA-approved drugs and existing compounds facing issues such as poor water solubility, stability, and lack of in vivo efficacy.
Innovation Solution
Development of novel pterostilbene amino acid bearing carbonates with improved water solubility and stability, synthesized through specific chemical reactions, for use in treating NAFLD and NASH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pterostilbene is used to treat NAFLD/NASH, then liver protection and therapeutic effects are achieved, but water solubility is poor (0.011 mg/mL)
Solution Approach 1:
The patent introduces amino acid carbonate groups as intermediary structures attached to the pterostilbene core. These amino acid bearing carbonates act as mediating moieties that provide water solubility while maintaining the parent compound's therapeutic activity. The amino acid side chains with polar groups serve as hydrophilic intermediaries between the lipophilic pterostilbene core and the aqueous biological environment.
Solution Approach 2:
The invention creates composite molecular structures by combining pterostilbene core with amino acid carbonate moieties. This composite approach integrates the lipophilic aromatic core responsible for therapeutic activity with hydrophilic amino acid chains that provide water solubility, resulting in a hybrid molecule that exhibits both desired pharmacological properties.
2Quantity of substance
If pterostilbene phosphate derivatives are developed to improve water solubility, then solubility increases, but stability is poor
Solution Approach 1:
The patent employs prodrug strategy where the amino acid carbonate derivatives serve as temporarily modified forms that are stable during administration but rapidly convert to the active pterostilbene form in vivo. The carbonate linkage is designed to be labile and short-lived, allowing the derivative to function as a stable delivery vehicle that releases the active compound when needed.
Solution Approach 2:
The invention changes the chemical parameters of pterostilbene by introducing amino acid carbonate groups that modify both solubility and metabolic stability. The carbonate linkage parameters are specifically chosen to provide enhanced stability compared to phosphate esters while maintaining hydrolyzability to release the active parent compound.
3Quantity of substance
If carbamate ester linkage is used in pterostilbene derivatives, then water solubility improves, but decomposition rate is slow
Solution Approach 1:
The patent applies local quality modification by attaching amino acid side chains with specific functional groups at particular positions on the pterostilbene core. The local chemical environment created by these amino acid moieties influences the decomposition rate of the carbonate linkage, providing controlled hydrolysis rates that balance solubility enhancement with appropriate metabolic conversion.
4Reliability
If lifestyle interventions are used for NASH treatment, then basic therapeutic effects are achieved, but compliance and maintenance are difficult
Solution Approach 1:
The amino acid carbonate derivatives function as self-service prodrugs that automatically convert to the active pterostilbene form in the body without requiring external intervention. The molecular design enables spontaneous hydrolysis by physiological enzymes, providing self-activating therapeutic agents that eliminate the need for complex administration regimens.
Data Source
AI summary
A series of novel analogs of water soluble pterostilbene amino acid bearing carbonates were synthesized, which show activities in treating a non-alcoholic fatty liver disease and a nonalcoholic steatohepatitis (NASH).